{"schema":"sb.node.v1","id":"sb:e/5ef18f84cd842245be55c36e","kind":"entity","label":{"text":"abbvie","locale":"en"},"identity":{"anchor":"label:en:abbvie","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-09T23:33:39.923351+00:00","snapshot":"deploy 28eb973c8e78d47cd7dc1d22314686757daeda65"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":98,"separatePublishers":30,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"measured","share":1,"named":10,"of":10,"basis":"receipts the entity graph keeps whose own headline names the subject, over all receipts it keeps for the subject (the door's measurement; the graph carries none of its own). Only the former are served"}},"admission":{"state":"canonical","reason":"entity graph provenance 'curated'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-04-30","to":"2026-10-08","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.214: about 79% of mentions carry no typed assertion"]}},"dimensions":{"domains":["auto","biotech_pharma","fda_decisions"],"activeDays":35,"assertions":{"regulatory-approval":9,"launch-release":3,"acquisition":2,"election":2,"military-action":1,"price-threshold":1}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":10,"byKind":{"observation":10},"withheld":{"state":"withheld","count":2,"reason":"2 receipts withheld: no source link (the same rule the topic record applies)"},"items":[{"id":"sb:o/8f6dac0764e6ee31ef089f40","kind":"observation","label":"Fierce Pharma · 2026-10-07 · AbbVie, Genmab score first-line DLBCL win for Epkinly, teeing up challenge to Roche's Polivy","url":"https://www.fiercepharma.com/pharma/abbvie-genmab-tout-ph3-first-line-win-epkinly-mounting-rivalry-roche"},{"id":"sb:o/e5ef8857b699233791fbf5d1","kind":"observation","label":"PR Newswire · 2026-10-07 · AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC","url":"https://www.prnewswire.com/news-releases/abbvies-telisotuzumab-adizutecan-temab-a-receives-two-breakthrough-therapy-designations-from-the-us-fda-for-crc-and-nsclc-302900512.html"},{"id":"sb:o/0eef975d20246b75293a7b81","kind":"observation","label":"AllSci News · 2026-10-06 · Genmab, AbbVie report 51% reduction in progression or death with frontline epcoritamab","url":"https://allsci.com/news/biotech/newly-diagnosed-dlbcl-epcoritamab-plus-r-chop/"},{"id":"sb:o/6649b6e8bc7a09eaa109331a","kind":"observation","label":"Endpoints News · 2026-10-06 · AbbVie, Genmab trot out first-line DLBCL win for Epkinly in challenge to Polivy","url":"https://endpoints.news/abbvie-genmab-trot-out-first-line-dlbcl-win-for-epkinly-in-challenge-to-polivy/"},{"id":"sb:o/2de311dbdf44b99e49b21e7f","kind":"observation","label":"Clinical Trials Arena · 2026-10-06 · AbbVie, Genmab report positive results from Phase III EPCORE DLBCL-2 trial","url":"https://www.clinicaltrialsarena.com/news/abbvie-genmab-positive-results-epcore-dlbcl-2-trial/"},{"id":"sb:o/e9505617dd7940369c6a8969","kind":"observation","label":"Fierce Biotech · 2026-10-05 · Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere","url":"https://www.fiercebiotech.com/biotech/genmab-data-spur-claim-adc-clearly-superior-abbvies-elahere"},{"id":"sb:o/04ae892d9d14e788f1a43bfb","kind":"observation","label":"AllSci News · 2026-10-02 · AbbVie’s zumilokibart clears Phase II with potential for quarterly or twice-yearly dosing","url":"https://allsci.com/news/biotech/zumilokibart-atopic-dermatitis-abbvies-cuts/"},{"id":"sb:o/d0109036116819e8f3ad57e5","kind":"observation","label":"Endpoints News · 2026-10-01 · AbbVie's eczema drug shows benefit in Phase 2; BioMarin lays off 117","url":"https://endpoints.news/abbvies-eczema-drug-shows-benefit-in-phase-2-biomarin-lays-off-117/"},{"id":"sb:o/b51c9a8cd91b08a6f8071254","kind":"observation","label":"24/7 Wall St. · 2026-09-30 · BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength","url":"https://247wallst.com/investing/2026/09/30/bofa-boosts-abbvie-and-jj-price-targets-on-growth-and-pipeline-strength/"},{"id":"sb:o/e7a6970546c9d46a6a209e8f","kind":"observation","label":"The Clinical Trial Vanguard · 2026-09-30 · AbbVie’s Zumilokibart Meets Primary Endpoint in Phase 2 Atopic Dermatitis Study","url":"https://www.clinicaltrialvanguard.com/news/abbvies-zumilokibart-meets-primary-endpoint-in-phase-2-atopic-dermatitis-study/"}],"cursor":null,"order":"newest first; we keep the 10 newest receipts for this entity whose own headline names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":{"state":"cannot-measure","reason":"claims: this subject's maintained record could not be read (the maintained record \"abbvie\" could not measure its claims: this subject was retired from the publication registry on 2026-09-22 (no longer clears the admission conditions — re-checked 2026-09-22 (no receipt in the corpus-evidence shard for this label)); the record is kept as a dated tombstone and is no longer maintained). The items listed come from the passes that could be read"},"byKind":{"co-mentioned":10},"items":[{"kind":"relation","label":"co-mentioned with fda (33 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/920c415fe141bcc215276113"},{"kind":"relation","label":"co-mentioned with eli lilly (21 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/92f6f2d54ef446da2ca38b78"},{"kind":"relation","label":"co-mentioned with merck (20 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/df54f4631e2dc8501d3bc744"},{"kind":"relation","label":"co-mentioned with amgen (19 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/cc6e4d440f9cc15cfdbcffca"},{"kind":"relation","label":"co-mentioned with pfizer (19 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/6c374a1f3ddef758235c83ba"},{"kind":"relation","label":"co-mentioned with roche (18 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/f51259e5d0d09382e615291d"},{"kind":"relation","label":"co-mentioned with nasdaq (17 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/274f9bd96523b0e6e4cebeee"},{"kind":"relation","label":"co-mentioned with novartis (16 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d0e4f7c0eda2089df1b16657"},{"kind":"relation","label":"co-mentioned with nyse (16 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/f39e1b664cf211e6aef91bd7"},{"kind":"relation","label":"co-mentioned with astrazeneca (15 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/e56500f6a6a5e4bc81173802"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/5ef18f84cd842245be55c36e","mcp":"traverse {\"id\":\"sb:e/5ef18f84cd842245be55c36e\"}","page":"/entity/abbvie/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/5ef18f84cd842245be55c36e\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/5ef18f84cd842245be55c36e\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/5ef18f84cd842245be55c36e\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/5ef18f84cd842245be55c36e\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}